Chris Loose, David L. Lucchino, Jeff Karp, Will McLean, Robert Langer
Total funding ($M)
sensorineural hearing loss
small molecule drugs
Phase 2 Trials
Creating a new class of medicines through Progenitor Cell Activation
We are a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases.
Our proprietary approach, called Progenitor Cell Activation (PCA) uses combinations of small molecules to activate progenitor cells within the body to create functional tissue.
Our initial therapeutic focus is for sensorineural hearing loss (SNHL), which is the most prevalent type of hearing loss. SNHL is typically caused by the permanent loss of sensory hair cells in the cochlea within the ear. FX-322, our lead product candidate, is intended to regenerate hair cells through the activation of progenitor cells already present in the cochlea.
Because of the broad applicability of our PCA approach, we are researching the potential of PCA across many different therapeutic areas including diseases of the central nervous system, muscle, gastrointestinal tract, skin, and bone.